Incyte reports positive PhI/II results; Bionovo gets relisted on NASDAQ;

@FierceBiotech: CEO: Roche, Genentech R&D won't merge. Story | Follow @FierceBiotech

@JohnCFierce: Boston Globe picked up on the big concentration of Fierce 15 companies in Boston. Story | Follow @JohnCFierce

> NASDAQ has informed women's health company Bionovo that it has regained compliance with the $1.00 minimum bid price. Bionovo release

> Incyte's drug INCB18424 for myelofibrosis eased symptoms of the disease in a study of 153 patients. If approved the drug, which is licensed by Novartis, would be the first treatment for the bone marrow disorder. Report

> Trading of Alkermes' shares was halted as an FDA expert panel reviews the company's sNDA for Vivitrol (extended-release injectable suspension) for opioid dependence. Alkermes release

> Immune Network plans to buy an oral vaccine technology platform from Immunitor. Immune Network release

And Finally... Duke University have discovered a gene responsible for nearsightedness in Caucasians. Report

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.